secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2026-05-15T12:00:31+00:00
Accession:  0001493152-26-023345
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences Q1 net loss narrows to $1.6M; cash position improved to $10.3M
--------------------------------------------------------------------------------

- Net loss $1.6M ($1.08 loss per share) vs $2.2M ($14.58) in Q1 2025; cash $4.9M at March 31.
- Raised gross $2.8M in Q1; subsequent $1.5M from warrant exercises and $5M upfront from $13.9M private placement.
- As of May 15, cash balance approx $10.3M; expects to fund EB-003 activities into Q1 2027.
- Advancing EB-003 toward IND; new preclinical data including PTSD model with rapid fear response reduction.
- AbbVie withdrew PGR petition against Enveric patent covering bretisilocin; strengthens IP portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/0001493152-26-023345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-023345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer